EUVIMEDScopri EUVIMED
Crossref

Linc‐ROR inhibits NK cell‐killing activity by promoting RXRA ubiquitination and reducing MICB expression in gastric cancer patients

Qingbin Niu, Zongrui Li, He Jiang, Baoguang Hu iD

Journal of Cellular Biochemistry · 2024

DOI: 10.1002/jcb.30516 ↗

At a glance

Journal article in Journal of Cellular Biochemistry, 2024. Written by Qingbin Niu and 3 co-authors. Institution: Department of Gastrointestinal Surgery, Dongying People's Hospital, Dongying, China. Major MEDLINE topics: RNA, Long Noncoding, Stomach Neoplasms. Cited 5 times so far (Crossref); 34 references. Funded by: Project of Medical and Health Technology Development Program in Shandong Province, Shandong Provincial Natural Science Foundation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Linc‐ROR plays an important role in gastric cancer (GC) development and progression. This study sought to determine how the aberrant expression of Linc‐ROR impacts GC progression and immune evasion, and to identify new targets for GC therapy. GC cells overexpressing Linc‐ROR and GSAGS cells were cocultured with NK‐92 cells, respectively, and Linc‐ROR expression was determined using reverse transcription polymerase chain reaction. Linc‐ROR overexpression experiments were used to measure the expression of MICB, a tumor protein that is recognized by natural killer (NK) cells. Bioinformatics analysis identified retinoid X receptor α (RXRA) and YY1 as MICB‐specific transcription factors. Cotransfection and ubiquitinated drug experiments found that Linc‐ROR promoted the ubiquitination and degradation of RXRA. Linc‐ROR was upregulated in GC tissue and high expression was associated with tumor escape from NK‐92 cell‐mediated immunity. Linc‐ROR overexpression inhibited the expression of MICB on the cell surface by degrading RXRA. These findings indicate that Linc‐ROR promotes the binding of RXRA and E3 ligase UBE4B, reducing RXRA and MICB expression, and limiting NK cell‐killing activity. Linc‐ROR is a critical long noncoding RNA with a tumor‐promoting function in GC and thus may serve as a potential therapeutic target.

Subjects

MeSH terms (MEDLINE)

RNA, Long NoncodingStomach NeoplasmsHumansCell Line, TumorKiller Cells, NaturalUbiquitin-Protein LigasesUbiquitinationHistocompatibility Antigens Class IRetinoid X Receptor alpha

Author keywords

Linc-RORNK cellsbioinformatic analysesgastric cancerubiquitinization

Substances

RNA, Long NoncodingUbiquitin-Protein LigasesMICB antigenHistocompatibility Antigens Class IRXRA protein, humanRetinoid X Receptor alphaUBE4B protein, humanLinc-RNA-RoR, human

Authors and institutions

  • Department of Gastrointestinal Surgery, Dongying People's Hospital, Dongying, China.
  • Department of Gastrointestinal Surgery, Binzhou Medical University Hospital, Binzhou, China.

ORCID profiles: Baoguang Hu

Funding

  • Project of Medical and Health Technology Development Program in Shandong Province
  • Shandong Provincial Natural Science Foundation

Cite

APA

Niu, Q., Li, Z., Jiang, H., & Hu, B. (2024). Linc‐ROR inhibits NK cell‐killing activity by promoting RXRA ubiquitination and reducing MICB expression in gastric cancer patients. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30516

Vancouver

Niu Q, Li Z, Jiang H, Hu B. Linc‐ROR inhibits NK cell‐killing activity by promoting RXRA ubiquitination and reducing MICB expression in gastric cancer patients. Journal of Cellular Biochemistry. 2024. doi:10.1002/jcb.30516

BibTeX
@article{Niu2024,
  author = {Niu, Qingbin and Li, Zongrui and Jiang, He and Hu, Baoguang},
  title = {Linc‐ROR inhibits NK cell‐killing activity by promoting RXRA ubiquitination and reducing MICB expression in gastric cancer patients},
  journal = {Journal of Cellular Biochemistry},
  year = {2024},
  doi = {10.1002/jcb.30516}
}
Start for free →